Bionano Genomics, Inc.

LSE:0A4K Stock Report

Market Cap: US$22.0m

Bionano Genomics Management

Management criteria checks 3/4

Bionano Genomics' CEO is Robert Holmlin, appointed in Jan 2011, has a tenure of 13.92 years. total yearly compensation is $1.25M, comprised of 47.7% salary and 52.3% bonuses, including company stock and options. directly owns 0.054% of the company’s shares, worth $11.98K. The average tenure of the management team and the board of directors is 3.6 years and 5.6 years respectively.

Key information

Robert Holmlin

Chief executive officer

US$1.3m

Total compensation

CEO salary percentage47.7%
CEO tenure13.9yrs
CEO ownership0.05%
Management average tenure3.6yrs
Board average tenure5.6yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Robert Holmlin's remuneration changed compared to Bionano Genomics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$136m

Jun 30 2024n/an/a

-US$204m

Mar 31 2024n/an/a

-US$227m

Dec 31 2023US$1mUS$599k

-US$232m

Sep 30 2023n/an/a

-US$227m

Jun 30 2023n/an/a

-US$147m

Mar 31 2023n/an/a

-US$140m

Dec 31 2022US$3mUS$544k

-US$133m

Sep 30 2022n/an/a

-US$117m

Jun 30 2022n/an/a

-US$106m

Mar 31 2022n/an/a

-US$92m

Dec 31 2021US$8mUS$484k

-US$72m

Sep 30 2021n/an/a

-US$61m

Jun 30 2021n/an/a

-US$51m

Mar 31 2021n/an/a

-US$41m

Dec 31 2020US$708kUS$376k

-US$41m

Sep 30 2020n/an/a

-US$37m

Jun 30 2020n/an/a

-US$33m

Mar 31 2020n/an/a

-US$32m

Dec 31 2019US$899kUS$404k

-US$30m

Sep 30 2019n/an/a

-US$28m

Jun 30 2019n/an/a

-US$27m

Mar 31 2019n/an/a

-US$23m

Dec 31 2018US$3mUS$390k

-US$18m

Sep 30 2018n/an/a

-US$18m

Jun 30 2018n/an/a

-US$18m

Mar 31 2018n/an/a

-US$22m

Dec 31 2017US$605kUS$379k

-US$23m

Compensation vs Market: Robert's total compensation ($USD1.25M) is above average for companies of similar size in the UK market ($USD345.59K).

Compensation vs Earnings: Robert's compensation has been consistent with company performance over the past year.

CEO

Robert Holmlin (56 yo)

13.9yrs

Tenure

US$1,254,658

Compensation

Dr. Robert Erik Holmlin, Ph D., M.B.A. has been the Chief Executive Officer and President of BioNano Genomics, Inc. (alternatively BioNanomatrix, Inc.) since January 12, 2011 and served as its Secretary &...

Leadership Team

NamePositionTenureCompensationOwnership
Robert Holmlin
President13.9yrsUS$1.25m0.054%
$ 12.0k
Mark Oldakowski
Chief Operating Officer7.1yrsUS$884.78k0.029%
$ 6.4k
Alka Chaubey
Chief Medical Officer4.3yrsUS$864.78k0.013%
$ 2.9k
Mark Adamchak
VP of Accounting & Controller6.5yrsno data0.016%
$ 3.6k
Jonathan Dixon
General Counsel & Secretary2.8yrsno data0.018%
$ 3.9k
Stanislas Marin
Vice President of Global Sales2.9yrsno datano data
Donna Polizio
Global Head of Market Access2.1yrsno datano data
Cory Kreeck
Global Head of People Operations2.9yrsno datano data

3.6yrs

Average Tenure

50.5yo

Average Age

Experienced Management: 0A4K's management team is considered experienced (3.6 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Robert Holmlin
President13.9yrsUS$1.25m0.054%
$ 12.0k
Christopher Twomey
Independent Director6.4yrsUS$72.75k0.0063%
$ 1.4k
David Barker
Independent Director14.6yrsUS$97.75k0.0057%
$ 1.3k
Albert Luderer
Independent Chairman13.2yrsUS$77.75kno data
Hannah Mamuszka
Independent Director4.6yrsUS$60.25k0.0065%
$ 1.4k
Kristiina Vuori
Independent Director5.6yrsUS$70.25kno data
Yvonne Linney
Independent Director4.6yrsUS$57.75kno data
Vincent Wong
Independent Director3yrsUS$62.75kno data
Aleksandar Rajkovic
Independent Director2.8yrsUS$57.75kno data

5.6yrs

Average Tenure

59yo

Average Age

Experienced Board: 0A4K's board of directors are considered experienced (5.6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/27 15:08
End of Day Share Price 2024/12/26 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Bionano Genomics, Inc. is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mark MassaroBTIG
Constantine DavidesD. Boral Capital LLC.
Jeffrey CohenLadenburg Thalmann & Company